MRONJ risk of adjuvant bisphosphonates in early stage breast cancer

被引：0
|
作者：
V. Patel
J. Mansi
S. Ghosh
J. Kwok
M. Burke
D. Reilly
N. Nizarali
C. Sproat
K. Chia
机构：
[1] Dept of Oral Surgery,Department of Oncology
[2] Guys & St Thomas' NHS Foundation Trust,undefined
[3] Fl 23,undefined
[4] Tower Wing,undefined
[5] Great Maze Pond,undefined
[6] London,undefined
[7] SE1 9RT,undefined
[8] Guys & St Thomas' NHS Foundation Trust,undefined
[9] Fl 23,undefined
[10] Tower Wing,undefined
[11] Great Maze Pond,undefined
[12] London,undefined
[13] SE1 9RT,undefined
[14] Sedation and Special Care,undefined
[15] Guys & St Thomas' NHS Foundation Trust,undefined
[16] Fl 23,undefined
[17] Tower Wing,undefined
[18] Great Maze Pond,undefined
[19] London,undefined
[20] SE1 9RT,undefined
来源：
British Dental Journal | 2018年 / 224卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Highlights that bisphosphonates continue to be the most common drug implicated in medication-related osteonecrosis of the jaw.Shows that an additional use of bisphosphonates has been indicated and now a further 20,000 women may be prescribed the medication and be exposed to the risk of jaw necrosis.Suggests the burden of additional dental assessment for these patients will fall upon GDPs.Introduces a new communication idea of the dental alert card which provides a warning to dentists for 'at risk' patients.
引用
收藏
页码：74 / 79
页数：5
相关论文
共 50 条
  • [21] Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
    Kizub, Darya A.
    Miao, Jieling
    Schubert, Mark M.
    Paterson, Alexander H. G.
    Clemons, Mark
    Dees, Elizabeth C.
    Ingle, James N.
    Falkson, Carla I.
    Barlow, William E.
    Hortobagyi, Gabriel N.
    Gralow, Julie R.
    SUPPORTIVE CARE IN CANCER, 2021, 29 (05) : 2509 - 2517
  • [22] Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
    Darya A. Kizub
    Jieling Miao
    Mark M. Schubert
    Alexander H. G. Paterson
    Mark Clemons
    Elizabeth C. Dees
    James N. Ingle
    Carla I. Falkson
    William E. Barlow
    Gabriel N. Hortobagyi
    Julie R. Gralow
    Supportive Care in Cancer, 2021, 29 : 2509 - 2517
  • [23] SCREENING WOMEN WITH EARLY STAGE BREAST CANCER AT RISK FOR CARDIAC DYSFUNCTION PRIOR TO ADJUVANT CANCER TREATMENT
    Richards, Rachel
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [24] Rethinking MRONJ risk in the prostate and breast cancer patient
    Atte, Antonio
    Radant, Matthew
    Tiwana, Paul
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2025, 139 (04): : 407 - 408
  • [25] The role of taxanes in the adjuvant treatment of early stage breast cancer
    Piccart, M
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 : S25 - S34
  • [26] The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer
    Martine Piccart
    Breast Cancer Research and Treatment, 2003, 79 (Suppl 1) : 25 - 34
  • [27] Acceptance of Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer
    Marcinkowski, E. F.
    Kauffman, R.
    Ottesen, R.
    Niland, J.
    Yuan, Y.
    Kruper, L.
    Taylor, L.
    Somlo, G.
    Waisman, J.
    Kim, J.
    Vito, C.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S59 - S59
  • [28] Overview of adjuvant systemic therapy in early stage breast cancer
    Newman, Lisa A.
    Singletary, S. Eva
    SURGICAL CLINICS OF NORTH AMERICA, 2007, 87 (02) : 499 - +
  • [29] Scheduling the adjuvant endocrine therapy for early stage breast cancer
    Sera Kahruman
    Elif Ulusal
    Sergiy Butenko
    Illya V. Hicks
    Kathleen M. Diehl
    Annals of Operations Research, 2012, 196 : 683 - 705
  • [30] Scheduling the adjuvant endocrine therapy for early stage breast cancer
    Kahruman, Sera
    Ulusal, Elif
    Butenko, Sergiy
    Hicks, Illya V.
    Diehl, Kathleen M.
    ANNALS OF OPERATIONS RESEARCH, 2012, 196 (01) : 683 - 705
12345